TY - JOUR
T1 - Sensing data and methodology from the Adaptive DBS Algorithm for Personalized Therapy in Parkinson’s Disease (ADAPT-PD) clinical trial
AU - On behalf of the ADAPT-PD Investigators
AU - Stanslaski, Scott
AU - Summers, Rebekah L.S.
AU - Tonder, Lisa
AU - Tan, Ye
AU - Case, Michelle
AU - Raike, Robert S.
AU - Morelli, Nathan
AU - Herrington, Todd M.
AU - Beudel, Martijn
AU - Ostrem, Jill L.
AU - Little, Simon
AU - Almeida, Leonardo
AU - Ramirez-Zamora, Adolfo
AU - Fasano, Alfonso
AU - Hassell, Travis
AU - Mitchell, Kyle T.
AU - Moro, Elena
AU - Gostkowski, Michal
AU - Sarangmat, Nagaraja
AU - Bronte-Stewart, Helen
N1 - Publisher Copyright:
© The Author(s) 2024.
PY - 2024/12
Y1 - 2024/12
N2 - Adaptive deep brain stimulation (aDBS) is an emerging advancement in DBS technology; however, local field potential (LFP) signal rate detection sufficient for aDBS algorithms and the methods to set-up aDBS have yet to be defined. Here we summarize sensing data and aDBS programming steps associated with the ongoing Adaptive DBS Algorithm for Personalized Therapy in Parkinson’s Disease (ADAPT-PD) pivotal trial (NCT04547712). Sixty-eight patients were enrolled with either subthalamic nucleus or globus pallidus internus DBS leads connected to a Medtronic PerceptTM PC neurostimulator. During the enrollment and screening procedures, a LFP (8–30 Hz, ≥1.2 µVp) control signal was identified by clinicians in 84.8% of patients on medication (65% bilateral signal), and in 92% of patients off medication (78% bilateral signal). The ADAPT-PD trial sensing data indicate a high LFP signal presence in both on and off medication states of these patients, with bilateral signal in the majority, regardless of PD phenotype.
AB - Adaptive deep brain stimulation (aDBS) is an emerging advancement in DBS technology; however, local field potential (LFP) signal rate detection sufficient for aDBS algorithms and the methods to set-up aDBS have yet to be defined. Here we summarize sensing data and aDBS programming steps associated with the ongoing Adaptive DBS Algorithm for Personalized Therapy in Parkinson’s Disease (ADAPT-PD) pivotal trial (NCT04547712). Sixty-eight patients were enrolled with either subthalamic nucleus or globus pallidus internus DBS leads connected to a Medtronic PerceptTM PC neurostimulator. During the enrollment and screening procedures, a LFP (8–30 Hz, ≥1.2 µVp) control signal was identified by clinicians in 84.8% of patients on medication (65% bilateral signal), and in 92% of patients off medication (78% bilateral signal). The ADAPT-PD trial sensing data indicate a high LFP signal presence in both on and off medication states of these patients, with bilateral signal in the majority, regardless of PD phenotype.
UR - https://www.scopus.com/pages/publications/85204454738
UR - https://www.scopus.com/pages/publications/85204454738#tab=citedBy
U2 - 10.1038/s41531-024-00772-5
DO - 10.1038/s41531-024-00772-5
M3 - Article
C2 - 39289373
AN - SCOPUS:85204454738
SN - 2373-8057
VL - 10
JO - npj Parkinson's Disease
JF - npj Parkinson's Disease
IS - 1
M1 - 174
ER -